Aspirin in pancreatic cancer : chemopreventive effects and therapeutic potentials
Copyright © 2016 Elsevier B.V. All rights reserved..
Pancreatic cancer is one of the most aggressive malignancies with dismal prognosis. Recently, aspirin has been found to be an effective chemopreventive agent for many solid tumors. However, the function of aspirin use in pancreatic cancer largely remains unknown. We herein argued that aspirin could also lower the risk of pancreatic cancer. Importantly, aspirin assumes pleiotropic effects by targeting multiple molecules. It could further target the unique tumor biology of pancreatic cancer and modify the cancer microenvironment, thus showing remarkable therapeutic potentials. Besides, aspirin could reverse the chemoradiation resistance by repressing tumor repopulation and exert synergistic potentials with metformin on pancreatic cancer chemoprevention. Moreover, aspirin secondarily benefits pancreatic cancer patients through modestly reducing cancer pain and the risk of venous thromboembolism. Furthermore, new aspirin derivatives and delivery systems might help to improve risk-to-benefit ratio. In brief, aspirin is a promising chemopreventive agent and exerts significant therapeutic potentials in pancreatic cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1866 |
|---|---|
| Enthalten in: |
Biochimica et biophysica acta - 1866(2016), 2 vom: 27. Dez., Seite 163-176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Ming-Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.06.2017 Date Revised 22.09.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbcan.2016.08.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM263817040 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM263817040 | ||
| 003 | DE-627 | ||
| 005 | 20231224204726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbcan.2016.08.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0879.xml |
| 035 | |a (DE-627)NLM263817040 | ||
| 035 | |a (NLM)27567928 | ||
| 035 | |a (PII)S0304-419X(16)30060-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Ming-Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aspirin in pancreatic cancer |b chemopreventive effects and therapeutic potentials |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2017 | ||
| 500 | |a Date Revised 22.09.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Elsevier B.V. All rights reserved. | ||
| 520 | |a Pancreatic cancer is one of the most aggressive malignancies with dismal prognosis. Recently, aspirin has been found to be an effective chemopreventive agent for many solid tumors. However, the function of aspirin use in pancreatic cancer largely remains unknown. We herein argued that aspirin could also lower the risk of pancreatic cancer. Importantly, aspirin assumes pleiotropic effects by targeting multiple molecules. It could further target the unique tumor biology of pancreatic cancer and modify the cancer microenvironment, thus showing remarkable therapeutic potentials. Besides, aspirin could reverse the chemoradiation resistance by repressing tumor repopulation and exert synergistic potentials with metformin on pancreatic cancer chemoprevention. Moreover, aspirin secondarily benefits pancreatic cancer patients through modestly reducing cancer pain and the risk of venous thromboembolism. Furthermore, new aspirin derivatives and delivery systems might help to improve risk-to-benefit ratio. In brief, aspirin is a promising chemopreventive agent and exerts significant therapeutic potentials in pancreatic cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Cancer biology | |
| 650 | 4 | |a Cancer chemoprevention | |
| 650 | 4 | |a Cancer microenvironment | |
| 650 | 4 | |a Cancer therapy | |
| 650 | 4 | |a Pancreatic cancer | |
| 650 | 7 | |a Anticarcinogenic Agents |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Dai, Juan-Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Dian-Na |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Ling |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta |d 1948 |g 1866(2016), 2 vom: 27. Dez., Seite 163-176 |w (DE-627)NLM000000698 |x 0006-3002 |7 nnns |
| 773 | 1 | 8 | |g volume:1866 |g year:2016 |g number:2 |g day:27 |g month:12 |g pages:163-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbcan.2016.08.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1866 |j 2016 |e 2 |b 27 |c 12 |h 163-176 | ||